CLINICAL_TRIALS
trial_result
· 2022-12-28
Clinical Trial Update: Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease [Phase 4]
Summary
Phase 4 clinical trial evaluating Feraheme as an MRI contrast agent in pediatric congenital heart disease has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Paul Finn | Conditions: Pediatric Congenital Heart Disease | Phase 4 | Status: COMPLETED | Results posted: 2022-12-28